×
Total revenue of $48.99 million beat the consensus estimate of roughly $47.29 million but declined about 13% year over year. GAAP (generally accepted accounting principles) net loss per share of -$0.67 was narrower than the consensus estimate of -$0.78.
Third quarter revenue reached $24.3 million , up 25% year over year and slightly above consensus estimates near $23.9 million. Net loss per share was ($0.24) , wider than the roughly ($0.13) consensus expectation but improved from ($0.30) a year earlier.
GoodRx Holdings (GDRX) is expected to report its third-quarter 2026 results after the market close on Tuesday, November 3, 2026, with a conference call scheduled for the following morning. Wall Street consensus points to earnings of roughly $0.08 per share and revenue of about $202 million for the quarter, compared with $0.08 per share and $196.0 million in the year-ago period.
SOPH shares declined roughly 22.8% over the trailing 30 days, falling from about $8.07 to near $6.23, even as revenue growth accelerated. The pullback erased much of a sharp summer rally, though the stock remains modestly higher over the trailing three-month period.
SOPHiA GENETICS shares slid from $7.11 to $6.35, a -10.69% drop, during Tuesday's regular session after opening lower following results. The decline followed a Q3 2026 earnings miss: adjusted EPS of -$0.24 versus the -$0.19 consensus and revenue of $24.3M slightly below the $24.5M estimate.
Waystar Holding (WAY) slid from a $28.14 prior close to $26.65 during regular market hours, a -5.29% decline. The drop extends post-earnings selling: Q3 results beat estimates (adjusted EPS $0.44 vs $0.41; revenue $325.6M), but fiscal 2026 revenue guidance was trimmed below consensus and implied a sequential Q4 revenue decline.
BEAT is an early-stage, pre-revenue cardiac monitoring developer, while IRTC is a scaled, revenue-generating digital health platform — a sharp contrast in maturity and risk. IRTC generates roughly $825 million in trailing revenue and is approaching profitability, whereas BEAT remains in early commercialization with ongoing net losses.
HealthStream reported third quarter 2026 revenue of $83.3 million , up 8.9% year over year and above analyst expectations. Diluted earnings per share (EPS) came in at $0.18 , topping consensus estimates even as it declined from $0.20 a year earlier.
Waystar reported third-quarter 2026 revenue of $325.6 million, up 21% year over year and slightly above the roughly $323.4 million consensus estimate. Non-GAAP diluted earnings per share (EPS) came in at $0.44, topping the $0.41 analyst consensus, while GAAP diluted EPS of $0.16 fell short of expectations.
Hinge Health (HNGE) reported third quarter 2026 revenue of $235 million, up 52% year over year and above Wall Street expectations. Adjusted earnings per share (EPS) reached $0.71, beating consensus estimates as the company delivered another beat-and-raise quarter.
Total revenue reached $411.5 million , up 23% year over year and ahead of the roughly $409 million consensus estimate. Adjusted earnings per share (EPS) came in at $0.07 , versus analyst expectations for a loss of $0.08 per share.
The $65 objective is a fallback, publicly discussed technical level just above the 52-week high — it is not an analyst-derived consensus target. The average analyst price target is about $50.50 , which is below the recent price near $59, meaning the stock has already outrun most Street targets.
HTFL fell -6.05% during Monday's regular session, dropping from a $59.05 previous close to $55.48. No verified news or fundamental catalyst found. The decline is consistent with profit-taking and technical correction after a roughly +25% run from ~$48 in mid-October to a 52-week high near $60, alongside recent insider selling by executives.
Net revenue rose 26.4% year over year to $4.21 billion, ahead of the roughly $3.87 billion consensus estimate. Adjusted EPS (earnings per share) of $0.54 topped the $0.47 analyst consensus by about 14.7%.
AMWL shares dropped -12.08% during regular market hours, falling from a previous close of $14.98 to $13.17. No verified news or fundamental catalyst found. The decline is consistent with profit-taking after a sharp run-up—shares had gained roughly +21% over the prior eight sessions into the Q3 earnings release due November 3 and were trading well above the ~$12.80 average analyst target.
Weave Communications (WEAV) is expected to report third-quarter 2026 results in early November 2026, estimated around November 4, after the U.S. market close. Wall Street consensus calls for non-GAAP earnings of $0.04 per share on revenue of roughly $69.2 million, up from $61.3 million in the prior-year quarter.
Omnicell reported third-quarter 2026 total revenue of $308 million, down 1% from $310.6 million a year earlier but above the high end of its own guidance range. Non-GAAP earnings per share (EPS) came in at $0.58, topping the roughly $0.42 consensus estimate by about 39% and up from $0.51 a year ago.
Simulations Plus, Inc. (NASDAQ: SLP), a provider of modeling and simulation software for drug development, is expected to report fiscal fourth quarter 2026 results (for the quarter ended August 31, 2026) after the market closes on Thursday, October 29, 2026. Wall Street consensus calls for earnings per share (EPS) of $0.09 on revenue of approximately $17.44 million, according to market estimates.
Schrödinger (SDGR) rose +13.44% during regular trading to roughly $30.31, up from a prior close of $26.72. The move had no company-specific catalyst and tracked a broad rally in AI-driven drug-discovery names (Absci +12%, Recursion +9%).
BEAT is up roughly +23.90% during regular market hours, with the latest intraday price near $0.496 versus the prior session close of $0.4004. The primary catalyst: HeartBeam announced its ALIGN-ACS pilot study results—132 ER chest-pain patients comparing its 3D ECG against a standard 12-lead ECG—will be presented at TCT 2026 on November 1.